Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features
Otolaryngology–Head and Neck Surgery · 2023
DOI: 10.1002/ohn.252 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2023. Written by Austin T Armstrong and 3 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, USA. Major MEDLINE topics: Extranodal Extension, Head and Neck Neoplasms. Cited 1 times so far (Crossref); 34 references.
Abstract (original language)
Objective
Determine trends and survival implications of adjuvant systemic therapy use for lower risk head and neck cancer. Study Design Retrospective cohort study.
Setting
US National Cancer Database, 2010 to 2019.
Methods
Patients with mucosal head and neck squamous cell carcinoma treated with surgery and postoperative radiation therapy were identified. Adjuvant systemic therapy trends in those with and without extranodal extension or positive margins were assessed as annual percent change by JoinPoint analysis. Factors associated with adjuvant systemic therapy and overall survival were assessed with multivariable models and cox proportional hazard models, respectively.
Results
From 2010 to 2019, approximately one‐third of head and neck cancer patients without extranodal extension or positive margins received adjuvant systemic therapy. This rate decreased throughout the study period, with the highest annual percent change from 2016 to 2019 (12.21%; 95% confidence interval: 3.73%‐19.95%). Younger age, male sex, Hispanic ethnicity, community program setting, advanced stage, and lymphovascular invasion increased the odds a patient would receive adjuvant systemic therapy. Adjuvant systemic therapy was associated with inferior overall survival when used in those without extranodal extension or positive margins after controlling for covariates.
Conclusion
Though decreasing, adjuvant systemic therapy use is still common in the absence of extranodal extension and positive margins, and a variety of patient, provider, and oncologic factors may influence its use. The inferior overall survival after adjuvant systemic therapy in the absence of high‐risk features suggests any oncologic benefit may not outweigh the costs and morbidity of the therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, USA.
ORCID profiles: Austin T Armstrong, Sean T Massa
Cite
APA
Armstrong, A. T., Velez-Velez, L. M., Simpson, M. C., & Massa, S. T. (2023). Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.252
Vancouver
Armstrong AT, Velez-Velez LM, Simpson MC, Massa ST. Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.252
BibTeX
@article{Armstrong2023,
author = {Armstrong, Austin T and Velez-Velez, Lisa M and Simpson, Matt C and Massa, Sean T},
title = {Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
doi = {10.1002/ohn.252}
}
EUVIMED